Acer Therapeutics Inc. (ACER): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACER Stock Price Chart Interactive Chart >
ACER Price/Volume Stats
| Current price | $2.88 | 52-week high | $5.84 |
| Prev. close | $2.92 | 52-week low | $2.15 |
| Day low | $2.83 | Volume | 89,700 |
| Day high | $2.91 | Avg. volume | 814,713 |
| 50-day MA | $2.85 | Dividend yield | N/A |
| 200-day MA | $2.94 | Market Cap | 41.21M |
Acer Therapeutics Inc. (ACER) Company Bio
Acer Therapeutics Inc., formerly Opexa Therapeutics, develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease. It also offers advancing ACER-001 for the treatment of urea cycle disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Latest ACER News From Around the Web
Below are the latest news stories about Acer Therapeutics Inc that investors may wish to consider to help them evaluate ACER as an investment opportunity.
Here is What Hedge Funds Think About Acer Therapeutics Inc. (ACER)No summary available. |
Acer Therapeutics (ACER) Receives a Hold from NeedhamNeedham analyst Serge Belanger maintained a Hold rating on Acer Therapeutics (ACER) today. The companys shares closed last Friday at $3. The post Acer Therapeutics (ACER) Receives a Hold from Needham appeared first on Smarter Analyst . |
Acer Therapeutics Plans Clinical Trial for EDSIVO (celiprolol) Following Type B FDA MeetingPhase 3, randomized, double-blind, placebo-controlled, decentralized clinical trial estimated to take approximately 3.5 years to complete once fully enrolled FDA indicates agreement with submission of proposed protocol under a Special Protocol Assessment (SPA) with possible breakthrough designation NEWTON, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical |
Acer Therapeutics Plans Clinical Trial for EDSIVO™ (celiprolol) Following Type B FDA MeetingPhase 3, randomized, double-blind, placebo-controlled, decentralized clinical trial estimated to take approximately 3.5 years to complete once fully enrolled FDA indicates agreement with submission of proposed protocol under a Special Protocol Assessment (SPA) with possible breakthrough designation NEWTON, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious |
What Makes Opexa Therapeutics, Inc. (ACER) a New Buy StockOpexa Therapeutics, Inc. (ACER) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
ACER Price Returns
| 1-mo | -0.35% |
| 3-mo | -26.15% |
| 6-mo | 11.63% |
| 1-year | -10.00% |
| 3-year | -85.04% |
| 5-year | -92.70% |
| YTD | 9.92% |
| 2020 | -34.66% |
| 2019 | -80.07% |
| 2018 | 45.27% |
| 2017 | 45.45% |
| 2016 | -66.79% |
Loading social stream, please wait...